AN13762 

AN13762 is a benzoxaborole antimalarial agent. AN13762 augments Plasmodium falciparum stress responses. AN13762 acts against cultured and fresh Plasmodium falciparum isolates and in vivo murine malaria models. AN13762 can be used for the research of malaria^[1].

AN13762 (1 nM-10 μM; 48 h) potently inhibits the growth of Plasmodium falciparum laboratory strains (3D7, W2, Dd2, 7G8, VS1, K1, D6) with IC₅₀ values ranging from 18 nM to 118 nM^[1].
AN13762 (72 h) potently inhibits the growth of fresh Plasmodium falciparum clinical isolates from Uganda^[1].
AN13762 (500 nM; 8 h) exhibits the greatest antimalarial activity against ring- and trophozoite-stage Plasmodium falciparum Dd2 parasites, causing abnormal trophozoite morphology and preventing further development^[1].
AN13762 produces low-level resistant Plasmodium falciparum (Dd2, 3D7, W2) with PfPARE mutations (IC₅₀ 180-1340 nM) and high-level resistant parasites with additional ubiquitination/sumoylation or PfCPSF3 mutations (IC₅₀ 1.1-5.0 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

355.15

C₁₇H₁₈BN₃O₅

2025371-99-5

O=C(N1CC(C)(C1)O)C2=CN=C(OC3=CC=C4C(B(OC4)O)=C3C)C=N2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sindhe KMV, et al. Plasmodium falciparum Resistance to a Lead Benzoxaborole Due to Blocked Compound Activation and Altered Ubiquitination or Sumoylation. mBio. 2020;11(1):e02640-19. Published 2020 Jan 28.